111 related articles for article (PubMed ID: 8956799)
1. The use of 99mTc-MIBI scanning in multiple myeloma.
Tirovola EB; Biassoni L; Britton KE; Kaleva N; Kouykin V; Malpas JS
Br J Cancer; 1996 Dec; 74(11):1815-20. PubMed ID: 8956799
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
3. Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience.
Villa G; Balleari E; Carletto M; Grosso M; Clavio M; Piccardo A; Rebella L; Tommasi L; Morbelli S; Peschiera F; Gobbi M; Ghio R
J Exp Clin Cancer Res; 2005 Sep; 24(3):355-61. PubMed ID: 16270521
[TBL] [Abstract][Full Text] [Related]
4. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease.
Balleari E; Villa G; Garrè S; Ghirlanda P; Agnese G; Carletto M; Clavio M; Ferrando F; Gobbi M; Mariani G; Ghio R
Haematologica; 2001 Jan; 86(1):78-84. PubMed ID: 11146575
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy.
Alper E; Gurel M; Evrensel T; Ozkocaman V; Akbunar T; Demiray M
Nucl Med Commun; 2003 May; 24(5):537-42. PubMed ID: 12717071
[TBL] [Abstract][Full Text] [Related]
6. Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma.
Pace L; Catalano L; Del Vecchio S; De Renzo A; Fonti R; Salvatore B; Andretta C; Di Nuzzo C; Rotoli B; Salvatore M
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):281-5. PubMed ID: 16172574
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m 2-methoxy-isobutyl-isonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: correlation with MRI and other prognostic factors.
Erten N; Saka B; Berberoglu K; Turkmen C; Unal S; Bakir B; Yekeler E; Besisik SK
Ann Hematol; 2007 Nov; 86(11):805-13. PubMed ID: 17684742
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation.
Svaldi M; Tappa C; Gebert U; Bettini D; Fabris P; Franzelin F; Osele L; Mitterer M
Ann Hematol; 2001 Jul; 80(7):393-7. PubMed ID: 11529464
[TBL] [Abstract][Full Text] [Related]
9. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.
Mele A; Offidani M; Visani G; Marconi M; Cambioli F; Nonni M; Catarini M; Brianzoni E; Berbellini A; Ascoli G; Brunori M; Agostini V; Corvatta L; Isidori A; Spinelli A; Gradari M; Leoni P
Br J Haematol; 2007 Mar; 136(5):729-35. PubMed ID: 17233770
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients.
Fallahi B; Beiki D; Mousavi SA; Gholamrezanezhad A; Eftekhari M; Fard-Esfahani A; Alimoghaddam K; Mirpour S; Eskandarian A; Saghari M
Hell J Nucl Med; 2009; 12(3):255-9. PubMed ID: 19936339
[TBL] [Abstract][Full Text] [Related]
11. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
[TBL] [Abstract][Full Text] [Related]
12. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate.
Alexandrakis MG; Kyriakou DS; Passam F; Koukouraki S; Karkavitsas N
Ann Hematol; 2001 Jun; 80(6):349-53. PubMed ID: 11475149
[TBL] [Abstract][Full Text] [Related]
13. Scintigraphy using (99m)Tc-MIBI (sestamibi), a sensitive parameter of activity of multiple myeloma.
Bacovsky J; Scudla V; Myslivecek M; Nekula J; Vytrasová M
Neoplasma; 2005; 52(4):302-6. PubMed ID: 16059646
[TBL] [Abstract][Full Text] [Related]
14. The value of 99mTc-MIBI whole body scintigraphy in active and in remission multiple myeloma.
Fallahi B; Saghari M; Fard Esfahani A; Eftekhari M; Iravani M; Beiki D; Dabbagh Kakhki VR; Sadeghi R
Hell J Nucl Med; 2005; 8(3):165-8. PubMed ID: 16390023
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma.
Fonti R; Del Vecchio S; Zannetti A; De Renzo A; Di Gennaro F; Catalano L; Califano C; Pace L; Rotoli B; Salvatore M
Eur J Nucl Med; 2001 Feb; 28(2):214-20. PubMed ID: 11303893
[TBL] [Abstract][Full Text] [Related]
16. Tc 99m Sestamibi Scanning in Multiple Myeloma--a New look with SPECT-CT.
Luthra K; Bhave A; Lele RD
J Assoc Physicians India; 2014 Sep; 62(9):801-12. PubMed ID: 26259316
[TBL] [Abstract][Full Text] [Related]
17. Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy.
Athanasoulis T; Koutsikos J; Moulopoulos LA; Tsiouris S; Dimopoulos MA; Zerva C
Clin Nucl Med; 2003 Aug; 28(8):631-5. PubMed ID: 12897645
[TBL] [Abstract][Full Text] [Related]
18. Different patterns of technetium-99m sestamibi uptake in multiple myeloma.
Pace L; Catalano L; Pinto A; De Renzo A; Di Gennaro F; Califano C; Del Vecchio S; Rotoli B; Salvatore M
Eur J Nucl Med; 1998 Jul; 25(7):714-20. PubMed ID: 9662593
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up.
Pace L; Catalano L; Del Vecchio S; Di Gennaro F; De Renzo A; Sica G; Califano C; Tedesco N; Borrelli G; Rotoli B; Salvatore M
Eur J Nucl Med; 2001 Mar; 28(3):304-12. PubMed ID: 11315597
[TBL] [Abstract][Full Text] [Related]
20. BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance.
Martín MG; Romero Colás MS; Dourdil Sahún MV; Olave P; Alba PR; Banzo JB
Haematologica; 2005 Aug; 90(8):1141-3. PubMed ID: 16079119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
